
Johan Franck

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/4481027/publications.pdf Version: 2024-02-01



#	Article	IF	CITATIONS
1	Naltrexone for the Treatment of Amphetamine Dependence: A Randomized, Placebo-Controlled Trial. American Journal of Psychiatry, 2008, 165, 1442-1448.	4.0	152
2	Variability in the prevalence of adult ADHD in treatment seeking substance use disorder patients: Results from an international multi-center study exploring DSM-IV and DSM-5 criteria. Drug and Alcohol Dependence, 2014, 134, 158-166.	1.6	150
3	Methylphenidate for attention deficit hyperactivity disorder and drug relapse in criminal offenders with substance dependence: a 24â€week randomized placeboâ€controlled trial. Addiction, 2014, 109, 440-449.	1.7	140
4	Validity of the Adult ADHD Self-Report Scale (ASRS) as a screener for adult ADHD in treatment seeking substance use disorder patients. Drug and Alcohol Dependence, 2013, 132, 587-596.	1.6	135
5	Psychiatric comorbidity in treatmentâ€seeking substance use disorder patients with and without attention deficit hyperactivity disorder: results of the <scp>IASP</scp> study. Addiction, 2014, 109, 262-272.	1.7	129
6	International Consensus Statement on Screening, Diagnosis and Treatment of Substance Use Disorder Patients with Comorbid Attention Deficit/Hyperactivity Disorder. European Addiction Research, 2018, 24, 43-51.	1.3	108
7	Pharmacotherapy for alcohol dependence: status of current treatments. Current Opinion in Neurobiology, 2013, 23, 692-699.	2.0	91
8	Naltrexone Attenuates the Subjective Effects of Amphetamine in Patients with Amphetamine Dependence. Neuropsychopharmacology, 2008, 33, 1856-1863.	2.8	89
9	Varenicline for Treatment of Alcohol Dependence: A Randomized, Placeboâ€Controlled Trial. Alcoholism: Clinical and Experimental Research, 2015, 39, 2189-2199.	1.4	89
10	The prevalence of mental health problems in elite athletes. Journal of Science and Medicine in Sport, 2020, 23, 329-335.	0.6	82
11	Phosphatidylethanol is Superior to Carbohydrateâ€Deficient Transferrin and <i>γ</i> â€Glutamyltransferase as an Alcohol Marker and is a Reliable Estimate of Alcohol Consumption Level. Alcoholism: Clinical and Experimental Research, 2015, 39, 2200-2208.	1.4	81
12	Mentalization-Based Treatment for Concurrent Borderline Personality Disorder and Substance Use Disorder: A Randomized Controlled Feasibility Study. European Addiction Research, 2018, 24, 1-8.	1.3	69
13	Attention-Deficit/Hyperactivity Disorder and Risk for Substance Use Disorders in Relatives. Biological Psychiatry, 2015, 77, 880-886.	0.7	61
14	The International ADHD in Substance Use Disorders Prevalence (IASP) study: background, methods and study population. International Journal of Methods in Psychiatric Research, 2013, 22, 232-244.	1.1	53
15	Modulation of Volitional Ethanol Intake in the Rat by Central delta-Opioid Receptors. Alcoholism: Clinical and Experimental Research, 1998, 22, 1185-1189.	1.4	46
16	Benzodiazepine prescribing for children, adolescents, and young adults from 2006 through 2013: A total population register-linkage study. PLoS Medicine, 2018, 15, e1002635.	3.9	42
17	An Epidemiological Study of ADHD, Substance Use, and Comorbid Problems in Incarcerated Women in Sweden. Journal of Attention Disorders, 2015, 19, 44-52.	1.5	38
18	Persistence and Subtype Stability of ADHD Among Substance Use Disorder Treatment Seekers. Journal of Attention Disorders, 2019, 23, 1438-1453.	1.5	34

JOHAN FRANCK

#	Article	IF	CITATIONS
19	The effects of the monoamine stabilizer (-)-OSU6162 on craving in alcohol dependent individuals: A human laboratory study. European Neuropsychopharmacology, 2015, 25, 2240-2251.	0.3	28
20	International Consensus Statement for the Screening, Diagnosis, and Treatment of Adolescents with Concurrent Attention-Deficit/Hyperactivity Disorder and Substance Use Disorder. European Addiction Research, 2020, 26, 223-232.	1.3	28
21	Childhood trauma exposure in substance use disorder patients with and without ADHD. Addictive Behaviors, 2017, 65, 118-124.	1.7	26
22	Associations of mental health and family background with opioid analgesic therapy: a nationwide Swedish register-based study. Pain, 2019, 160, 2464-2472.	2.0	24
23	Association of Opioid Prescription Initiation During Adolescence and Young Adulthood With Subsequent Substance-Related Morbidity. JAMA Pediatrics, 2020, 174, 1048.	3.3	24
24	Methylphenidate doses in Attention Deficit/Hyperactivity Disorder and comorbid substance use disorders. European Neuropsychopharmacology, 2017, 27, 1144-1152.	0.3	22
25	Factors Associated With Adherence to Methylphenidate Treatment in Adult Patients With Attention-Deficit/Hyperactivity Disorder and Substance Use Disorders. Journal of Clinical Psychopharmacology, 2016, 36, 222-228.	0.7	21
26	Drug abuse screening with exhaled breath and oral fluid in adults with substance use disorder. Drug Testing and Analysis, 2019, 11, 27-32.	1.6	19
27	The International Collaboration on ADHD and Substance Abuse (ICASA): Mission, Results, and Future Activities. European Addiction Research, 2020, 26, 173-178.	1.3	15
28	Prevalence and comorbidity of psychiatric disorders among treatment-seeking elite athletes and high-performance coaches. BMJ Open Sport and Exercise Medicine, 2022, 8, e001264.	1.4	14
29	Effect of alcohol use disorder family history on cognitive function. Psychological Medicine, 2022, 52, 757-769.	2.7	13
30	Risk Factors for Borderline Personality Disorder in Treatment Seeking Patients with a Substance Use Disorder: An International Multicenter Study. European Addiction Research, 2015, 21, 188-194.	1.3	11
31	Cue reactivity and opioid blockade in amphetamine dependence: A randomized, controlled fMRI study. Drug and Alcohol Dependence, 2018, 191, 91-97.	1.6	10
32	Self-rated impulsivity in healthy individuals, substance use disorder and ADHD: psychometric properties of the Swedish Barratt impulsiveness scale. BMC Psychiatry, 2021, 21, 458.	1.1	10
33	Family History of Alcohol Abuse Associated with Higher Impulsivity in Patients with Alcohol Use Disorder: A Multisite Study. European Addiction Research, 2020, 26, 85-95.	1.3	8
34	Validity of the ADHD module of the Mini International Neuropsychiatric Interview PLUS for screening of adult ADHD in treatment seeking substance use disorder patients: ADHD screening with MINI-Plus. Revista De PsiquiatrÃa Y Salud Mental, 2020, , .	1.0	6
35	Effects ofÂtheÂmonoamine stabilizer (-)OSU6162 onÂcognitive function inÂalcohol dependence. Psychopharmacology, 2020, 237, 69-82.	1.5	5
36	Early developmental, temperamental and educational problems in â€~substance use disorder' patients with and without ADHD. Does ADHD make a difference?. Addictive Behaviors Reports, 2015, 2, 13-18.	1.0	4

Johan Franck

#	Article	IF	CITATIONS
37	Alcohol and drug use prior to liver transplantation: more common than expected in patients with non-alcoholic liver disease. Scandinavian Journal of Gastroenterology, 2019, 54, 1146-1154.	0.6	3
38	Methylphenidate effects on processing speed in a clinical sample of adults with ADHD and substance use disorder: a pilot study. Nordic Journal of Psychiatry, 2019, 73, 118-124.	0.7	3
39	Substance Use, Hospitalizations, and Co-Occurring Disorders among Patients Transferred from a Needle Exchange Program to Opioid Maintenance Treatment. International Journal of Environmental Research and Public Health, 2022, 19, 697.	1.2	2
40	Plasma concentrations of methylphenidate enantiomers in adults with ADHD and substance use disorder, with focus on high doses and relationship to carboxylesterase activity. Basic and Clinical Pharmacology and Toxicology, 2022, 130, 492-500.	1.2	2
41	<i>CYP3A4*22</i> and <i>CYP3A5*3</i> impact efficacy and safety of diazepam in patients with alcohol withdrawal syndrome. Nordic Journal of Psychiatry, 2023, 77, 73-76.	0.7	2
42	Initiation of Opioid Prescription and Risk of Suicidal Behavior Among Youth and Young Adults. Pediatrics, 2022, 149, .	1.0	1
43	The Hypothesis of Subliminal Cue Reactivity in Addiction Revisited: An fMRI Study. European Addiction Research, 2022, 28, 210-219.	1.3	0